Analysts' outlook on Abbott Laboratories remains steady, des...
Analysts' outlook on Abbott Laboratories remains steady, despite projected slowdown in revenue growth to 4.6% annually until 2024, well below its historical 7.9% p.a. growth and slower than industry peers.
Earnings Update: Abbott Laboratories (NYSE:ABT) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment